Products for Research Use Only

Phenformin

CAT: 0804-HY-16397-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16397-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Phenformin (1-phenethylbiguanide) is an orally active antidiabetic and anticancer agent. Phenformin has an incidence of associated lactic acidosis. Phenformin acts through acting AMPK activation and blocking mTOR pathway. Phenformin is also a substrate of P-glycoprotein (P-gp), and an OXPHOS inhibitor. Phenformin induces cancer cell apoptosis[1][2].
CAS Number
114-86-3
Product Name Alternative
Phenethylbiguanide
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
AMPK; Apoptosis; Mitochondrial Metabolism
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/phenformin.html
Purity
99.72
Solubility
H2O : 350 mg/mL (ultrasonic)
Smiles
NC(NC(NCCC1=CC=CC=C1)=N)=N
Molecular Formula
C10H15N5
Molecular Weight
205.26
Precautions
H302, H315, H319, H335
References & Citations
[1]García Rubiño ME, et al. Phenformin as an Anticancer Agent: Challenges and Prospects. Int J Mol Sci. 2019 Jul 5;20 (13) :3316.|[2]Yendapally R, et al. A review of phenformin, metformin, and imeglimin. Drug Dev Res. 2020 Jun;81 (4) :390-401.
Shipping Conditions
Room Temperature
Storage Conditions
RT, protect from light
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Int J Biol Macromol. 2025 Aug 21;323 (Pt 1) :147047.|ACS Omega. 2022 Jan 18;7 (4) :3293-3311.|Biomed Pharmacother. 2020 Aug;128:110216.|Cell Rep Med. 2022 Nov 15;3 (11) :100802.|Life Sci. 2019 Jan 15:217:243-250.|Mol Syst Biol. 2023 Jul 11;19 (7) :e11267.|Nat Commun. 2019 Jul 1;10 (1) :2901. |Pharmaceuticals (Basel) . 2024 Sep 19;17 (9) :1234.